HGH Fragment 176-191

HGH Fragment 176-191 is the C-terminal 16-amino-acid fragment of human growth hormone, isolated specifically for the lipolytic portion of the parent hormone without the IGF-1 or glucose effects.

Imagine taking growth hormone and snipping out only the slice that tells fat cells to release stored fat — that is HGH Frag 176-191. It is studied as the fat-loss-only segment of GH.

Believed to act on beta-3 adrenergic receptors on adipocytes, stimulating lipolysis and inhibiting lipogenesis without engaging GH receptors that drive IGF-1.

Isolated fat-burning portion of HGH. No IGF-1 elevation, no mass gain, no insulin resistance.

1. HGH Fragment 176-191
2. GHRH and/or ghrelin receptors in the pituitary
3. Pulsatile growth hormone release
4. Downstream IGF-1, body-composition and recovery endpoints

A plain-English read on how much published evidence currently exists for HGH Fragment 176-191. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of HGH Fragment 176-191.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 10 units = 250mcg
• • 20 units = 500mcg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

250–500mcg daily, fasted (or split 2–3×)

Commonly cited frequency

Daily AM fasted, or split 2–3× daily

Commonly cited study duration

8–12 weeks

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Lipolysis and fat oxidation studies
• •Body composition research
• •Comparison with AOD9604 and full HGH
• •Beta-3 adrenergic pathway research

Discussed in fat-loss and recomp circles as a targeted alternative to full GH or GLP-1s. Common debate: HGH Frag vs AOD9604.

“The fat-loss-only piece of growth hormone.”

Often layered on top of CJC-1295/Ipamorelin protocols, or compared with AOD9604, Tesamorelin, and GLP-1 receptor agonists.

HGH Fragment 176-191 is the C-terminal fat-loss fragment of growth hormone, studied for lipolysis without IGF-1 or glucose effects.